Translational cognitive biomarkers for preclinical drug testing in neurodegenerative diseases
The lack of Cinpanemab efficacy in our pre-clinical testing pipeline aligns with clinical trial results. The effectiveness of PU-AD in reducing both cognitive and motor impairments suggests it may have broad therapeutic potential in synucleinopathies. We suggest that touchscreen-based cognitive testing enhances the predictive validity of preclinical drug evaluation.
Authors
- Thomas M. Durcan (ORCID: https://orcid.org/0000-0003-3942-1956)
- Anoosha Attaran (ORCID: https://orcid.org/0000-0001-7090-2331)
- Edward A. Fon (ORCID: https://orcid.org/0000-0002-5520-6239)
- Irina Shlaifer (ORCID: https://orcid.org/0000-0002-3737-268X)
- Vânia F. Prado (ORCID: https://orcid.org/0000-0003-4994-6393)
- Czarina Evangelista (ORCID: https://orcid.org/0000-0002-7745-5252)
- Sahil Sharma
- Vladislav Novikov
- Marco AM Prado
- Amr Eed
- Gabriela Chiosis
- Man Ching Yau
- Lisa M Saksida
- Timothy J Bussey
- Yasmien Abduldayem
- M. Mallar Chakravarty
- Rodrigo Sandoval
- Mohammad‐Hossein Tabatabaei
- Ravi S. Menon
- Matthew Cowan
- Wen Luo
Institutions
- Western University (CA)
- Montreal Neurological Institute and Hospital (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Douglas Mental Health University Institute (CA)
- Kettering University (US)
- Robarts Clinical Trials (CA)
- Ontario Brain Institute (CA)
- McGill University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_103517
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00